BiomX (NYSEMKT:PHGE) Trading 277.5% Higher – Time to Buy?

BiomX Inc. (NYSEMKT:PHGE)’s stock price shot up 277.5% on Tuesday . The stock traded as high as $0.7762 and last traded at $2.79. 53,300 shares were traded during trading, a decline of 85% from the average session volume of 347,190 shares. The stock had previously closed at $0.7390.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating on shares of BiomX in a research report on Tuesday, November 25th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, BiomX has an average rating of “Buy” and an average price target of $399.00.

BiomX Trading Up 277.5%

The firm has a market cap of $4.26 million, a price-to-earnings ratio of -3.72 and a beta of 1.60. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.51. The company has a 50 day moving average of $3.32 and a 200 day moving average of $7.33.

Institutional Investors Weigh In On BiomX

An institutional investor recently bought a new position in BiomX stock. Citadel Advisors LLC bought a new stake in BiomX Inc. (NYSEMKT:PHGE) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned 0.61% of BiomX as of its most recent SEC filing. Hedge funds and other institutional investors own 40.57% of the company’s stock.

BiomX Company Profile

BiomX Ltd. is a clinical-stage biotechnology company developing targeted bacteriophage therapies designed to modulate the human microbiome. The company’s proprietary platform combines computational analytics with phage biology to identify and engineer virus-based agents that selectively target disease-associated bacteria without disrupting beneficial microbial communities. Through this precision approach, BiomX aims to address unmet needs in gastrointestinal and dermatological disorders driven by microbial dysbiosis.

BiomX’s pipeline includes investigational products for conditions such as Crohn’s disease, ulcerative colitis and acne.